Table 1. Patient characteristics of the overall study population, and of patients with aspirin monotherapy (ASA) vs. dual antiplatelet therapy (ASA+Clo).
| Characteristics | Overall (n = 562) | ASA (n = 371) | ASA+Clo (n = 191) | p |
|---|---|---|---|---|
| Age, years | 61.6 ± 0.5 | 62 ± 1 | 61 ± 1 | 0.2 |
| Sex, % male | 65.3 | 63.9 | 68.1 | 0.3 |
| BMI, kg/m2 | 30 ± 0.3 | 30.2 ± 0.3 | 29.7 ± 0.4 | 0.5 |
| Medical history, % | ||||
| Prior MI | 23.7 | 20.3 | 30.4 | 0.008 |
| Prior stroke | 3.9 | 3.2 | 5.2 | 0.3 |
| Hypertension | 72.2 | 72.8 | 71.2 | 0.7 |
| Hyperlipidemia | 83.5 | 82.2 | 85.9 | 0.3 |
| Diabetes mellitus | 28.5 | 30.5 | 24.6 | 0.1 |
| Active smoking | 19.4 | 19.9 | 18.3 | 0.7 |
| Laboratory data | ||||
| Platelet count, x 109/L | 229 ± 3 | 227 ± 3 | 232 ± 6 | 0.8 |
| White blood cells, x 109/L | 7.1 ± 0.1 | 7.1 ± 0.1 | 7 ± 0.2 | 0.2 |
| Hematocrit, % | 39.8 ± 0.2 | 40 ± 0.2 | 39.4 ± 0.3 | 0.1 |
| High-sensitivity CRP, mg/L | 8 ± 0.8 | 7.8 ± 0.9 | 8.4 ± 1.6 | 0.4 |
| Reason for catheterization, % | ||||
| Positive exercise tolerance test | 37.4 | 41.9 | 28.6 | 0.002 |
| Chest pain | 17.2 | 17.6 | 16.4 | 0.7 |
| Stable angina | 17.7 | 17.6 | 18 | 0.9 |
| Unstable angina | 15.2 | 10.5 | 24.3 | <0.001 |
| Non-ST-segment elevation MI | 6.4 | 4.9 | 9.5 | 0.03 |
| ST-segment elevation MI | 0.7 | 0.5 | 1.1 | 0.6 |
| Other | 5.4 | 7 | 2.1 | 0.02 |
| Angiography result, % | ||||
| Coronary artery disease | 81.7 | 80.9 | 83.2 | 0.5 |
| Stent implantation | 36.5 | 34.8 | 39.8 | 0.2 |
| Medication pre-intervention, % | ||||
| Aspirin | 100 | 100 | 100 | 1 |
| Statin | 68.5 | 63.9 | 77.5 | 0.001 |
| ACE inhibitor | 42.3 | 41.5 | 44 | 0.6 |
| Beta blocker | 73.8 | 76.5 | 68.6 | 0.04 |
| Calcium channel blocker | 23.7 | 21.6 | 27.7 | 0.1 |
| Proton pump inhibitor | 31 | 28.3 | 36.1 | 0.06 |
Continuous data are shown as mean ± SEM. Dichotomous data are shown as %.
Abbreviations: ACE, angiotensin converting enzyme; BMI, body mass index; CRP, C-reactive protein; MI, myocardial infarction.